SCHEMBL18619476

SCHEMBL18619476

O=C(NC1CCSC1=O)c1cc(O)ccc1O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.58
KMT2A Q03164 2/20 0.58
MEN1 O00255 1/20 0.58
ALDH1A1 P00352 6/20 0.56
TAS1R3 Q7RTX0 2/20 0.55
TAS1R1 Q7RTX1 2/20 0.55
TAS1R2 Q8TE23 2/20 0.55
PKM P14618 1/20 0.52
GAA P10253 1/20 0.50
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPK1 P28482 2/20 0.47
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14830534 0.83 KMT2A (0.72) POLBKMT2AMEN1ALDH1A1PKM
SCHEMBL18619386 0.79 POLB (0.72) POLBKMT2AMEN1ALDH1A1PKM
SCHEMBL10511025 0.74 KMT2A (0.72) POLBKMT2AMEN1ALDH1A1PKM
SCHEMBL13634694 0.73 KMT2A (1.00) POLBKMT2AMEN1ALDH1A1PKM
SCHEMBL3462955 0.72 ALDH1A1 (1.00) POLBKMT2AMEN1ALDH1A1PKM
SCHEMBL704676 0.71 TAS1R3 (1.00) KMT2AMEN1ALDH1A1TAS1R3TAS1R1
SCHEMBL704675 0.71 TAS1R3 (1.00) KMT2AMEN1ALDH1A1TAS1R3TAS1R1
SCHEMBL14830862 0.70 KMT2A (0.55) POLBKMT2AMEN1ALDH1A1MAPK1
SCHEMBL12505245 0.68 ALDH1A1 (0.62) POLBKMT2AMEN1ALDH1A1MAPK1
SCHEMBL11256738 0.67 ALDH1A1 (0.56) POLBKMT2AMEN1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-08-04 US claimed
US-20180251472-A1 Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2018-09-06 US claimed
EP-3345910-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME Shin Poong Pharmaceutical Co., Ltd. (KR) 2018-07-11 EP claimed
EP-3345910-B1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2023-11-01 EP disclosed
EP-3345910-B1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2023-11-01 EP disclosed
CN-108602837-B Compound having platelet aggregation inhibitory effect, salt thereof, and composition for preventing or treating thrombotic diseases comprising same 新丰制药株式会社 2022-02-11 CN disclosed
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-08-04 US disclosed
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-08-04 US disclosed
US-20180251472-A1 Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2018-09-06 US disclosed
EP-3345910-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME Shin Poong Pharmaceutical Co., Ltd. (KR) 2018-07-11 EP disclosed
EP-3345910-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME Shin Poong Pharmaceutical Co., Ltd. (KR) 2018-07-11 EP disclosed
WO-2017039395-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME 신풍제약 주식회사 2017-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251472-A1 Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same PLA2G7, JAK2, PF4 POLB 4037/4885KMT2A 3505/4885MEN1 2227/4885
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same PLA2G7, JAK2, PF4 POLB 4037/4885KMT2A 3505/4885MEN1 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.